Stocktoria
Armata Pharmaceuticals, Inc. ARMP
NYSE American · XASE · stock · Biological Products, (No Diagnostic Substances) · website · IPO 1994-05-20
Armata Pharmaceuticals, Inc. financials (annual, from 10-K)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| R&D expense | — | — | — | — | — | — | $9.8M | $8.4M | $2.9M | $5.7M |
| Operating income | -$36.6M | -$42.4M | -$40.9M | -$36.9M | -$23.8M | -$21.6M | -$19.8M | -$17.7M | -$16.2M | -$23.4M |
| Interest expense | — | — | — | $0 | $64,000 | $628,000 | $931,000 | $1.0M | — | $6,000 |
| Income tax | — | — | — | — | — | — | — | -$328,000 | -$1.3M | -$556,000 |
| Net income | -$173.8M | -$18.9M | -$69.0M | -$36.9M | -$23.2M | -$22.2M | -$19.5M | -$16.7M | -$12.8M | -$18.8M |
| EPS (diluted) | $-4.80 | $-0.89 | $-1.91 | $-1.08 | $-0.96 | $-1.35 | $-2.55 | $-3.59 | $-2.18 | $-24.67 |
| Operating cash flow | -$25.8M | -$37.6M | -$47.4M | -$32.5M | -$23.6M | -$18.3M | -$15.6M | -$10.6M | -$9.2M | -$10.6M |
| Free cash flow | -$26.3M | -$39.4M | -$55.6M | -$34.7M | -$24.9M | -$19.1M | -$15.8M | -$11.5M | -$9.2M | -$10.9M |
| Cash & equivalents | $8.7M | $9.3M | $13.5M | $14.9M | $10.3M | $9.6M | $6.0M | $9.7M | $5.1M | $5.1M |
| Total assets | $76.9M | $86.4M | $98.4M | $95.8M | $69.8M | $39.5M | $25.5M | $14.5M | $11.1M | $18.2M |
| Total liabilities | $295.5M | $134.5M | $130.4M | $59.8M | $44.4M | $20.7M | $10.9M | $6.9M | $3.4M | $8.4M |
| Shareholders' equity | -$218.6M | -$48.0M | -$32.1M | $36.1M | $25.4M | $18.9M | $14.6M | $7.7M | $24.3M | $9.7M |
Source: SEC EDGAR filings · CIK 0000921114 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.